This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of ASC40
Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival
Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC
Novartis India has reported total income of Rs. 106.50 crores during the period ended December 31, 2023
Astec LifeSciences has reported total income of Rs. 51.70 crores during the period ended December 31, 2023
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
Laurus Labs has reported total income of Rs. 1197.35 crores during the period ended December 31, 2023
Aarti Drugs has reported total income of Rs. 607.61 crores during the period ended December 31, 2023
Hearing restoration was observed within 30 days of a single administration of AK-OTOF in the initial AK-OTOF-101 study participant
Cipla has reported total income of Rs. 6,788.44 crores during the period ended December 31, 2023
Subscribe To Our Newsletter & Stay Updated
